Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1979 2
1980 5
1981 4
1982 8
1983 8
1984 7
1985 3
1986 5
1987 6
1988 1
1989 2
1991 1
1992 2
1993 1
1996 3
1998 2
1999 1
2000 2
2001 1
2003 1
2004 1
2005 2
2006 1
2007 1
2011 1
2012 2
2013 3
2014 1
2015 1
2016 4
2017 2
2018 2
2019 6
2020 2
2021 4
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Moreau P, et al. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097854 Clinical Trial.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Attal M, et al. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Lancet. 2019. PMID: 31735560 Clinical Trial.
Idiopathic erythrocytosis--a declining entity.
Blacklock HA, Royle GA. Blacklock HA, et al. Br J Haematol. 2001 Dec;115(4):774-81. doi: 10.1046/j.1365-2141.2001.03168.x. Br J Haematol. 2001. PMID: 11843808 Free article. Review. No abstract available.
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
McQuilten Z, Wellard C, Moore E, Augustson B, Bergin K, Blacklock H, Harrison S, Ho PJ, King T, Quach H, Mollee P, Rosengarten B, Walker P, Wood E, Spencer A; Australian and New Zealand Myeloma and Related Diseases Registry. McQuilten Z, et al. Among authors: blacklock h. Br J Haematol. 2022 Sep;198(5):830-837. doi: 10.1111/bjh.18324. Epub 2022 Jul 11. Br J Haematol. 2022. PMID: 35818641 Free PMC article.
Plasma exchange in Goodpasture's syndrome.
Simpson IJ, Doak PB, Williams LC, Blacklock HA, Hill RS, Teague CA, Herdson PB, Wilson CB. Simpson IJ, et al. Among authors: blacklock ha. Am J Nephrol. 1982;2(6):301-11. doi: 10.1159/000166666. Am J Nephrol. 1982. PMID: 6762091
The hypereosinophilic syndrome and leukapheresis.
Blacklock HA, Cleland JF, Tan P, Pillai VM. Blacklock HA, et al. Ann Intern Med. 1979 Oct;91(4):650-1. doi: 10.7326/0003-4819-91-4-650_2. Ann Intern Med. 1979. PMID: 484976 No abstract available.
Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
Moore EM, Blacklock H, Wellard C, Spearing R, Merriman L, Poplar S, George A, Baker B, Chan H, McQuilten ZK, Wood EM, Spencer A; MRDR investigators. Moore EM, et al. Among authors: blacklock h. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e762-e769. doi: 10.1016/j.clml.2022.04.004. Epub 2022 Apr 8. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35501256
97 results